Scientists discuss obstacles preventing implementation of new HIV drug

In an article published in the journal AIDS Patient Care and STDs, researchers said they believe that a newly developed oral drug called pre-exposure prophylaxis (PrEP) may help prevent HIV infection. However, the scientists discussed several barriers that must be addressed before the medication becomes available to individuals in high-risk populations.

According to the results from a PrEP trial, the combination antiretroviral treatment cut the incidence of HIV among participants in half.

Although the researchers said that they found these results to be promising, they believe that another phase of studies that focus on the side effects and sustainability of the treatment regimen is necessary before PrEP is publicly introduced. It is possible that individuals who do not strictly adhere to the drug schedule would reduce its efficacy.

The investigators also noted that the high cost of the treatment may limit its accessibility.

According to the Centers for Disease Control and Prevention, more than 1.1 million Americans are infected with HIV.

Anyone who is at high risk of contracting the virus, including homosexual men and individuals who engage in unprotected sex, may consider using online testing services to be screened for sexually transmitted diseases.